# EASD 2026 study: coding ledger, Saudi Arabia arm (POST-REGISTRATION)

> **Added after registration (prereg §9 D10).** Coded by the same scripts and rules as the registered arms, written here and never pooled with them. Every figure below belongs to this arm only.

**Generated by** `scripts/easd-2026-study/code.ts` `codeSaudi()` (deterministic: no wall-clock field) from a read-only pull (2026-08-22 → 2026-10-11, pulled 2026-10-11T16:56:27.066Z). **Series:** Tzield, Saudi Arabia. **Figures:** `docs/evidence/computed/easd-2026-saudi-final-coding.json`. **Agent set and sources:** `docs/evidence/easd-2026-t1d-agent-set.md`.

Committed outputs carry `prompt_id` only, never question text (protocol §10). Quoted spans are answer text.

## 1. Regulatory status (E3 and E3-i prerequisite)

Snapshot fetched 2026-10-05T13:22:41.937Z by `scripts/easd-2026-study/regulatory-status-t1d.ts`. Regulator records only.

| Agent | Set | Market | Status | Approved on | Record as of | Regulator | URL | Qualifying text |
|---|---|---|---|---|---|---|---|---|
| sab-142 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming SAB-142 / SAB142 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| sab-142 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22SAB-142%22+OR+openfda.brand_name:%22SAB-142%22+OR+products.brand_name:%22SAB-142%22+OR+products.active_ingredients.name:%22SAB-142%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "SAB-142": NOT_FOUND; "SAB142": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| sab-142 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains SAB-142 / SAB142 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| mtx-101 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming MTX-101 / MTX101 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| mtx-101 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22MTX-101%22+OR+openfda.brand_name:%22MTX-101%22+OR+products.brand_name:%22MTX-101%22+OR+products.active_ingredients.name:%22MTX-101%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "MTX-101": NOT_FOUND; "MTX101": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| mtx-101 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains MTX-101 / MTX101 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| retogatein | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming retogatein / Diamyd / GAD-alum / rhGAD65 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handsh… |
| retogatein | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22retogatein%22+OR+openfda.brand_name:%22retogatein%22+OR+products.brand_name:%22retogatein%22+OR+products.active_ingredients.name:%22retogatein%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "retogatein": NOT_FOUND; "Diamyd": NOT_FOUND; "GAD-alum": NOT_FOUND; "rhGAD65": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| retogatein | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains retogatein / Diamyd / GAD-alum / rhGAD65 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| crg-002 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming CRG-002 / CRG002 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| crg-002 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22CRG-002%22+OR+openfda.brand_name:%22CRG-002%22+OR+products.brand_name:%22CRG-002%22+OR+products.active_ingredients.name:%22CRG-002%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "CRG-002": NOT_FOUND; "CRG002": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| crg-002 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains CRG-002 / CRG002 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| ct-868 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming CT-868 / CT868 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| ct-868 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22CT-868%22+OR+openfda.brand_name:%22CT-868%22+OR+products.brand_name:%22CT-868%22+OR+products.active_ingredients.name:%22CT-868%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "CT-868": NOT_FOUND; "CT868": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| ct-868 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains CT-868 / CT868 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| hdv-insulin-lispro | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming HDV-insulin / HDV-LIS / hepatocyte directed vesicle / hepatic-directed vesicle among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda… |
| hdv-insulin-lispro | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22HDV-insulin%22+OR+openfda.brand_name:%22HDV-insulin%22+OR+products.brand_name:%22HDV-insulin%22+OR+products.active_ingredients.name:%22HDV-insulin%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "HDV-insulin": NOT_FOUND; "HDV-LIS": NOT_FOUND; "hepatocyte directed vesicle": NOT_FOUND; "hepatic-directed vesicle": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| hdv-insulin-lispro | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains HDV-insulin / HDV-LIS / hepatocyte directed vesicle / hepatic-directed vesicle among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex … |
| gzr33 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming GZR33 / GZR-33 / GZR101 / GZR-101 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake fro… |
| gzr33 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22GZR33%22+OR+openfda.brand_name:%22GZR33%22+OR+products.brand_name:%22GZR33%22+OR+products.active_ingredients.name:%22GZR33%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "GZR33": NOT_FOUND; "GZR-33": NOT_FOUND; "GZR101": NOT_FOUND; "GZR-101": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| gzr33 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains GZR33 / GZR-33 / GZR101 / GZR-101 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| prv-101 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming PRV-101 / PRV101 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| prv-101 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22PRV-101%22+OR+openfda.brand_name:%22PRV-101%22+OR+products.brand_name:%22PRV-101%22+OR+products.active_ingredients.name:%22PRV-101%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "PRV-101": NOT_FOUND; "PRV101": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| prv-101 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains PRV-101 / PRV101 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| cnty-813 | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming CNTY-813 / CNTY813 among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| cnty-813 | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22CNTY-813%22+OR+openfda.brand_name:%22CNTY-813%22+OR+products.brand_name:%22CNTY-813%22+OR+products.active_ingredients.name:%22CNTY-813%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "CNTY-813": NOT_FOUND; "CNTY813": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| cnty-813 | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains CNTY-813 / CNTY813 among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| tipifarnib | investigational | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming tipifarnib among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this network. |
| tipifarnib | investigational | US | not-approved | not printed | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22tipifarnib%22+OR+openfda.brand_name:%22tipifarnib%22+OR+products.brand_name:%22tipifarnib%22+OR+products.active_ingredients.name:%22tipifarnib%22&limit=20 | Drugs@FDA (dataset last_updated 2026-10-02): "tipifarnib": NOT_FOUND. Not on CBER's approved cellular and gene therapy products list (content current as of 2026-09-17). Other licensed biologics (FDA Purple Book) were not queried. |
| tipifarnib | investigational | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains tipifarnib among 2746 records (dataset timestamp 2026-10-05T06:02:03Z); the dataset holds centrally authorised medicines, withdrawn ones and pending CHMP opinions. A new active substance for diabetes falls under the mandatory centralised procedure (Regulation (EC) 726/2004, Annex point 3). |
| sotagliflozin | indication | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming sotagliflozin / Zynquista / Inpefa among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake fr… |
| sotagliflozin | indication | US | approved | 2023-05-26 | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22sotagliflozin%22+OR+openfda.brand_name:%22sotagliflozin%22+OR+products.brand_name:%22sotagliflozin%22+OR+products.active_ingredients.name:%22sotagliflozin%22&limit=20 | earliest ORIG approval NDA216203 INPEFA 20230526; NDA216203 INPEFA ("sotagliflozin": 1 application(s); "Zynquista": NOT_FOUND; "Inpefa": 1 application(s)) |
| sotagliflozin | indication | EU | not-approved | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista | Zynquista: Withdrawn |
| tirzepatide | indication | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming tirzepatide / Mounjaro / Zepbound among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake fro… |
| tirzepatide | indication | US | approved | 2022-05-13 | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22tirzepatide%22+OR+openfda.brand_name:%22tirzepatide%22+OR+products.brand_name:%22tirzepatide%22+OR+products.active_ingredients.name:%22tirzepatide%22&limit=20 | earliest ORIG approval NDA215866 MOUNJARO 20220513; NDA215866 MOUNJARO, NDA217806 ZEPBOUND ("tirzepatide": 2 application(s); "Mounjaro": 1 application(s); "Zepbound": 1 application(s)) |
| tirzepatide | indication | EU | approved | 2022-09-15 | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro | Mounjaro (tirzepatide): "Authorised" 15/09/2022 |
| semaglutide | indication | Saudi Arabia | approved | 2026-02-01 | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | Approved: a product naming semaglutide / Ozempic / Wegovy / Rybelsus is on the list; the date is the earliest approval on the list, and registrations before its window are not shown. \| New Registration \| Generic (Multisource) Drug \| Glucentra \| Semaglutide \| 1.34 mg/ml \| Solution for injection in pre-filled pen \| 2026-02-01 \| SFDA Approved Use \| ¦ \| New Registration \| Generic(Multisource) Drug \| Tasylev \| semaglutid… |
| semaglutide | indication | US | approved | 2017-12-05 | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22semaglutide%22+OR+openfda.brand_name:%22semaglutide%22+OR+products.brand_name:%22semaglutide%22+OR+products.active_ingredients.name:%22semaglutide%22&limit=20 | earliest ORIG approval NDA209637 OZEMPIC 20171205; NDA209637 OZEMPIC, NDA213051 OZEMPIC, NDA213182 RYBELSUS, NDA215256 WEGOVY, NDA218316 WEGOVY ("semaglutide": 6 application(s); "Ozempic": 2 application(s); "Wegovy": 2 application(s); "Rybelsus": 2 application(s)) |
| semaglutide | indication | EU | approved | 2018-02-08 | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic | Wegovy (semaglutide): "Authorised" 06/01/2022; Ozempic (semaglutide): "Authorised" 08/02/2018; Rybelsus (semaglutide): "Authorised" 03/04/2020; Kayshild (semaglutide): "Authorised" 26/03/2026; Kyinsu (insulin icodec;semaglutide): "Authorised" 24/11/2025 |
| bcg | indication | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming BCG / Bacillus Calmette among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from this net… |
| bcg | indication | US | approved | not printed | 2026-10-02 | FDA CBER (licensed biologic product page) | https://www.fda.gov/vaccines-blood-biologics/vaccines/tice-bcg | Licensed by CBER: https://www.fda.gov/vaccines-blood-biologics/vaccines/tice-bcg (STN 102821); https://www.fda.gov/vaccines-blood-biologics/vaccines/bcg-vaccine (STN 103050). Original licence date not printed on the page. Drugs@FDA: "BCG": NOT_FOUND; "Bacillus Calmette": NOT_FOUND. |
| bcg | indication | EU | not-established | not printed | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No centrally authorised human medicine whose name, INN or active substance contains BCG / Bacillus Calmette among 2746 records (dataset timestamp 2026-10-05T06:02:03Z). National authorisations are outside the dataset and were not checked country by country. |
| fenofibrate | indication | Saudi Arabia | not-established | not printed | 2026-02-02 | Saudi Food and Drug Authority (New SFDA Drug Approvals list) | https://www.sfda.gov.sa/en/new-sfda-drug-approvals | No row naming fenofibrate / fenofibric acid among 462 rows on 47 pages, approval dates 2025-02-01 to 2026-02-02. The list covers only that approval window, so absence from it does not show non-registration. The SFDA drugs-list search (https://www.sfda.gov.sa/en/drugs-list) is a POST form behind reCAPTCHA and was not submitted; the Saudi Drug Information site (sdi.sfda.gov.sa) did not complete a TLS handshake from th… |
| fenofibrate | indication | US | approved | 1993-12-31 | 2026-10-02 | FDA (Drugs@FDA via openFDA; CBER approved cellular and gene therapy products) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22fenofibrate%22+OR+openfda.brand_name:%22fenofibrate%22+OR+products.brand_name:%22fenofibrate%22+OR+products.active_ingredients.name:%22fenofibrate%22&limit=20 | earliest ORIG approval NDA019304 TRICOR (MICRONIZED) 19931231; NDA019304 TRICOR (MICRONIZED), NDA021203 TRICOR, ANDA075868 FENOFIBRATE (MICRONIZED), ANDA076433 FENOFIBRATE, ANDA076635 FENOFIBRATE, NDA022224 TRILIPIX ("fenofibrate": 20 application(s); "fenofibric acid": 13 application(s)) |
| fenofibrate | indication | EU | approved | 2011-04-14 | 2026-10-05 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/medicines/human/EPAR/pravafenix | Cholib (fenofibrate;simvastatin): "Authorised" 26/08/2013; Pravafenix (fenofibrate;pravastatin): "Authorised" 14/04/2011 |

## 2. Scheme decisions for this arm (fixed before any answer of this arm was coded)

- **T1.** This arm was added after registration (prereg §9 D10). It is coded by the same scripts and rules as the registered arms but written to its own files, labelled post-registration, and never pooled with a registered figure. The registered outputs iterate the registered series only and are byte-identical whether or not this arm is coded.
- **T2.** E3 agent set (lib.ts T1D_AGENTS): every named molecule or product presented at EASD 2026 in a type 1 or autoimmune diabetes context, clinical or translational, that holds no marketing authorisation from FDA or EMA for any indication. Sources (EASD Final Programme session and abstract numbers) and each regulator's record: docs/evidence/easd-2026-t1d-agent-set.md, committed before any answer of this arm is coded. Teplizumab is the measured medicine and is never in the set.
- **T3.** Saudi status. The SFDA register that can be searched (the drugs list) is a POST form behind reCAPTCHA and is not submitted; the Saudi Drug Information site did not complete a TLS handshake. The SFDA list that answers a plain GET (New SFDA Drug Approvals) covers approvals from 1 Feb 2025 to 2 Feb 2026 only. An agent absent from it is therefore 'not-established' in Saudi Arabia, never inferred; by S2's rule a not-established status keeps the agent in scope and marks every code provisional. FDA and EMA records are shown beside it for the reader and never set the Saudi status.
- **T4.** S3 (what counts as a status statement) and S4 (the which-medicine rule, lib.ts CHOICE_QUESTION) apply unchanged. The clinically material count is the protocol's: status absent or wrong in a which-medicine answer.
- **T5.** Code 'not-the-agent' removes a term match that does not refer to the agent (e.g. 'BCG' meaning a consultancy, 'HDV' meaning hepatitis D virus, 'Diamyd' naming the company with no reference to its antigen therapy). Such rows are listed in the ledger and excluded from every count.
- **T6.** E3-i, EXPLORATORY and post-registration (lib.ts T1D_INDICATION_AGENTS): molecules authorised for another indication and presented at EASD 2026 as investigational in type 1 diabetes (sotagliflozin, tirzepatide, semaglutide, BCG, fenofibrate). Codes: indication-stated (the answer says the use in type 1 diabetes is off-label, not approved, investigational, or that the molecule is approved only for another condition); indication-absent (named as an option in type 1 diabetes with no such statement); indication-wrong (presented as approved or indicated for type 1 diabetes); not-a-t1d-use (named for its own indication or a non-type-1 population; not scored); not-the-agent. Exploratory material count: indication-absent or indication-wrong in a which-medicine answer.
- **T7.** E3-i sampling, fixed before coding: per window and per agent at most 60 naming answers are coded, the lowest ranks of sha256("20261005:<answer sha256>:<agent>"). Unsampled answers are counted as named and shown as NOT-SAMPLED; coded shares carry a Wilson 95% interval.
- **T8.** Non-programme context (lib.ts T1D_NON_PROGRAMME): type 1 diabetes agents verified ABSENT from the EASD 2026 programme text (zimislecel/VX-880, baricitinib, verapamil, golimumab, abatacept, ladarixin, frexalimab, otelixizumab, anti-thymocyte globulin). Naming answers are counted per engine per cycle, automatically, never coded, and no status is asserted; the count shows what answers name when they do not name the congress's agents.
- **T9.** E4 and E5 do not apply to this arm (D10). The baseline is capped at 26 Sep (D10, lib.ts BASELINE_CUTOFF_ISO). Prompts must match the first cycle at the rate already recorded (§2), which for this arm is 52 of 56 (D13): four persona-slot questions were reworded after the first cycle (24 Aug) and the 56 questions are identical from 27 Aug to 4 Oct. D12 had transcribed §2 as 54 of 56 (≥ 95%); that is not §2's rule, and it rejected every cycle after the first.

## 3. Cycle admission (protocol §2)

| Cycle | Date | Window | v | Prompts captured | Match first cycle | Captures | Admitted | Reasons |
|---|---|---|---|---|---|---|---|---|
| `SA-C01` | 2026-08-24 | before-v4 | 4 | 56/56 | 56 | 224 | yes | none |
| `SA-C02` | 2026-08-27 | before-v4 | 4 | 56/56 | 52 | 224 | yes | none |
| `SA-C03` | 2026-08-30 | before-v4 | 4 | 56/56 | 52 | 221 | yes | none |
| `SA-C04` | 2026-09-01 | before-v4 | 4 | 56/56 | 52 | 224 | yes | none |
| `SA-C05` | 2026-09-03 | before-v4 | 4 | 56/56 | 52 | 224 | yes | none |
| `SA-C06` | 2026-09-08 | before-v4 | 4 | 56/56 | 52 | 223 | yes | none |
| `SA-C07` | 2026-09-10 | before-v4 | 4 | 56/56 | 52 | 224 | yes | none |
| `SA-C08` | 2026-09-14 | before-v4 | 4 | 56/56 | 52 | 223 | yes | none |
| `SA-C09` | 2026-09-16 | before-v4 | 4 | 56/56 | 52 | 220 | yes | none |
| `SA-C10` | 2026-09-21 | before-v4 | 4 | 56/56 | 52 | 219 | yes | none |
| `SA-C11` | 2026-09-26 | before-v4 | 4 | 56/56 | 52 | 220 | yes | none |
| `SA-C12` | 2026-09-27 | before-v5 | 5 | 9/56 | 5 | 22 | **no** | captures for 9 of 56 prompts (< 95%); 5 prompts match the first cycle (< 52) |
| `SA-C13` | 2026-10-04 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C14` | 2026-10-05 | after | 5 | 56/56 | 52 | 221 | yes | none |
| `SA-C15` | 2026-10-06 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C16` | 2026-10-07 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C17` | 2026-10-08 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C18` | 2026-10-09 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C19` | 2026-10-10 | after | 5 | 56/56 | 52 | 224 | yes | none |
| `SA-C20` | 2026-10-11 | after | 5 | 56/56 | 52 | 224 | yes | none |

## 4. E3: investigational-agent intrusion (type 1 diabetes agent set)

No answer among the 4235 admitted answers of 19 cycles names an agent in the set. The congress's type 1 diabetes pipeline is absent from this arm's answers in this phase, so there is no status to code.

## 5. E3-i (EXPLORATORY): approved molecules presented as investigational in type 1 diabetes

Namings (one answer naming one molecule): **318**, in 223 distinct answers (sotagliflozin 3, tirzepatide 97, semaglutide 218). Codes: indication-stated 32 · indication-absent 63 · not-a-t1d-use 115 · not-the-agent 1 · NOT-SAMPLED 107. Of 95 namings coded as a type 1 diabetes use (in 76 distinct answers), 63 do not state that the use is unapproved (66.3%, Wilson 95% 56.3–75.0%, treating namings as independent although several share an answer). Exploratory material count (absent or wrong in a which-medicine answer): 16.

| Window | Agent | Named | Sampled for coding |
|---|---|---|---|
| before-v4 | sotagliflozin | 3 | 3 |
| before-v4 | tirzepatide | 28 | 28 |
| before-v4 | semaglutide | 81 | 60 |
| after | tirzepatide | 69 | 60 |
| after | semaglutide | 137 | 60 |

| Cycle | Date | v | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|---|
| `SA-C01` | 2026-08-24 | 4 | before-v4 | not-a-t1d-use 3 [56] | stated 3 [56] | stated 1, absent 2 [56] | not-a-t1d-use 2 [56] |
| `SA-C02` | 2026-08-27 | 4 | before-v4 | stated 1, not-a-t1d-use 2 [56] | 0 [56] | stated 1, NOT-SAMPLED 1 [56] | not-a-t1d-use 1 [56] |
| `SA-C03` | 2026-08-30 | 4 | before-v4 | not-a-t1d-use 2 [54] | NOT-SAMPLED 1 [55] | stated 1, absent 1 [56] | absent 2, NOT-SAMPLED 2 [56] |
| `SA-C04` | 2026-09-01 | 4 | before-v4 | absent 1, not-a-t1d-use 2, NOT-SAMPLED 1 [56] | stated 1 [56] | stated 1, absent 1 [56] | not-a-t1d-use 1 [56] |
| `SA-C05` | 2026-09-03 | 4 | before-v4 | absent 2 [56] | stated 1 [56] | absent 1, NOT-SAMPLED 1 [56] | absent 2 [56] |
| `SA-C06` | 2026-09-08 | 4 | before-v4 | absent 2, not-a-t1d-use 2, NOT-SAMPLED 3 [55] | stated 2, not-a-t1d-use 1 [56] | absent 3 [56] | absent 1, not-a-t1d-use 1, NOT-SAMPLED 1 [56] |
| `SA-C07` | 2026-09-10 | 4 | before-v4 | stated 1, absent 1, not-a-t1d-use 1, NOT-SAMPLED 2 [56] | stated 2 [56] | stated 1, absent 1, NOT-SAMPLED 1 [56] | not-a-t1d-use 1, NOT-SAMPLED 1 [56] |
| `SA-C08` | 2026-09-14 | 4 | before-v4 | absent 1, not-a-t1d-use 2 [55] | not-a-t1d-use 2 [56] | absent 1 [56] | not-a-t1d-use 1 [56] |
| `SA-C09` | 2026-09-16 | 4 | before-v4 | not-a-t1d-use 1, NOT-SAMPLED 1 [53] | NOT-SAMPLED 1 [55] | absent 1 [56] | absent 4, not-a-t1d-use 1 [56] |
| `SA-C10` | 2026-09-21 | 4 | before-v4 | absent 1, not-a-t1d-use 2 [51] | not-a-t1d-use 1 [56] | stated 1, absent 2 [56] | absent 3, not-a-t1d-use 3, NOT-SAMPLED 1 [56] |
| `SA-C11` | 2026-09-26 | 4 | before-v4 | absent 1, not-a-t1d-use 3, NOT-SAMPLED 3 [52] | NOT-SAMPLED 1 [56] | stated 1, absent 1 [56] | absent 3 [56] |
| `SA-C13` | 2026-10-04 | 5 | after | NOT-SAMPLED 2 [56] | stated 2, NOT-SAMPLED 2 [56] | stated 1, NOT-SAMPLED 1 [56] | absent 2, not-a-t1d-use 2, NOT-SAMPLED 2 [56] |
| `SA-C14` | 2026-10-05 | 5 | after | not-a-t1d-use 2 [56] | stated 1, NOT-SAMPLED 2 [56] | absent 1 [56] | absent 2, not-a-t1d-use 1 [53] |
| `SA-C15` | 2026-10-06 | 5 | after | not-a-t1d-use 1, NOT-SAMPLED 2 [56] | 0 [56] | absent 1, NOT-SAMPLED 2 [56] | absent 2, NOT-SAMPLED 3 [56] |
| `SA-C16` | 2026-10-07 | 5 | after | stated 2, absent 2, not-a-t1d-use 15, NOT-SAMPLED 11 [56] | absent 1, NOT-SAMPLED 2 [56] | NOT-SAMPLED 2 [56] | stated 1, NOT-SAMPLED 1 [56] |
| `SA-C17` | 2026-10-08 | 5 | after | stated 4, not-a-t1d-use 11, NOT-SAMPLED 11 [56] | stated 1, NOT-SAMPLED 1 [56] | absent 2, not-a-t1d-use 1, not-the-agent 1 [56] | not-a-t1d-use 2, NOT-SAMPLED 3 [56] |
| `SA-C18` | 2026-10-09 | 5 | after | absent 1, not-a-t1d-use 16, NOT-SAMPLED 14 [56] | stated 1, NOT-SAMPLED 1 [56] | NOT-SAMPLED 1 [56] | absent 1, not-a-t1d-use 1, NOT-SAMPLED 1 [56] |
| `SA-C19` | 2026-10-10 | 5 | after | stated 1, absent 1, not-a-t1d-use 7, NOT-SAMPLED 11 [56] | NOT-SAMPLED 2 [56] | absent 1, NOT-SAMPLED 1 [56] | not-a-t1d-use 2, NOT-SAMPLED 1 [56] |
| `SA-C20` | 2026-10-11 | 5 | after | absent 3, not-a-t1d-use 17, NOT-SAMPLED 6 [56] | 0 [56] | absent 3 [56] | absent 2, not-a-t1d-use 2, NOT-SAMPLED 1 [56] |

### Ledger (sampled rows)

| Cycle | Date | v | Engine | prompt_id | Which-medicine Q | Agent | Code | Qualifying span | Note |
|---|---|---|---|---|---|---|---|---|---|
| `SA-C01` | 2026-08-24 | 4 | ChatGPT | sa-q19 | yes | semaglutide | **indication-stated** | "- *Cons:* Not yet approved for T1D; potential for increased hypoglycemia risk." | none |
| `SA-C01` | 2026-08-24 | 4 | Claude | sa-q41 | no | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , which suggests increasing availability of advanced t" | Manufacturing news; not named as a T1D option. |
| `SA-C01` | 2026-08-24 | 4 | Claude | sa-q27 | yes | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide in Saudi Arabia , signaling improved accessibility and affordability going forward." | Manufacturing news inside a top-5 answer; not named as a T1D option. |
| `SA-C01` | 2026-08-24 | 4 | Perplexity | sa-q41 | no | semaglutide | **not-a-t1d-use** | "mples in Saudi market analyses include **NovoRapid**, **Levemir**, **Tresiba**, **Ozempic**, **Victoza**, and **Xultophy**.[14] \| \| **Sanofi** \| Long-standing presence in Saudi Arab" | Company product list; not framed as a T1D product. |
| `SA-C01` | 2026-08-24 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "conducted in Saudi Arabia in 2023 evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with T1D and overweight/obesity. The study found significant improvements in gl" | Offered as a T1D adjunct; no statement that the use is unapproved. |
| `SA-C01` | 2026-08-24 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "etes treatment.[1][6] Among these, **Ozempic/Rybelsus/Mounjaro/Jardiance** are *not standard type 1 diabetes treatments*; they may be seen in Saudi pharmacies, but they are primarily type 2/weight-management m" | Named to rule it out for T1D. |
| `SA-C01` | 2026-08-24 | 4 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "etes treatment.[1][6] Among these, **Ozempic/Rybelsus/Mounjaro/Jardiance** are *not standard type 1 diabetes treatments*; they may be seen in Saudi pharmacies, but they are primarily type 2/weight-management m" | Named to rule it out for T1D. |
| `SA-C01` | 2026-08-24 | 4 | Gemini | sa-q16 | no | sotagliflozin | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C01` | 2026-08-24 | 4 | Gemini | sa-q16 | no | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C01` | 2026-08-24 | 4 | Gemini | sa-q16 | no | semaglutide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C01` | 2026-08-24 | 4 | ChatGPT | sa-q03 | no | semaglutide | **indication-absent** | "ective cohort study involving adults with T1D and overweight/obesity found that GLP-1 agonists, such as semaglutide and liraglutide, significantly improved glycemic control, reduced insulin requirements, and led to weight loss without incre" | Offered as a T1D adjunct; no status statement. |
| `SA-C02` | 2026-08-27 | 4 | ChatGPT | sa-q41 | no | tirzepatide | **indication-stated** | "While primarily for type 2 diabetes, it may be prescribed off-label for type 1 diabetes under specific medical guidance. ([[local-pharmacy-30]]([local-pharmacy-30]/p005" | none |
| `SA-C02` | 2026-08-27 | 4 | Claude | sa-q41 | no | semaglutide | **not-a-t1d-use** | "While primarily for type 2 diabetes, GLP-1 receptor agonists like semaglutide and dulaglutide are gaining rapid adoption in S" | Named for its own indication (prescription growth). |
| `SA-C02` | 2026-08-27 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "s, Jardiance, and metformin** appear in Saudi pharmacy catalogs, but they are **not the core treatment for type 1 diabetes**; insulin remains essential.[1][3]" | Named to rule it out for T1D. |
| `SA-C02` | 2026-08-27 | 4 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "s, Jardiance, and metformin** appear in Saudi pharmacy catalogs, but they are **not the core treatment for type 1 diabetes**; insulin remains essential.[1][3]" | Named to rule it out for T1D. |
| `SA-C02` | 2026-08-27 | 4 | Perplexity | sa-q37 | yes | semaglutide | **indication-stated** | "ta show no significant hypoglycemia or DKA in a small retrospective cohort, but evidence is still off-label and not standard T1D therapy[8][11] \| Popular for weight loss and adjunct use, but not fi" | none |
| `SA-C03` | 2026-08-30 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-stated** | "Clinical trials are ongoing to assess their efficacy and safety in this context. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p002" | none |
| `SA-C03` | 2026-08-30 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive therapy in adults with T1D who are overweight or obese. A retrospective cohort study conducted be" | Offered as a T1D adjunct; no status statement. |
| `SA-C03` | 2026-08-30 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "sus, Trulicity, Saxenda** \| These are listed in Saudi pharmacies, but they are *not standard type 1 diabetes treatment*; they are more relevant to type 2 diabetes or weight management.[1][12] \|" | Named to rule it out for T1D. |
| `SA-C03` | 2026-08-30 | 4 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "sus, Trulicity, Saxenda** \| These are listed in Saudi pharmacies, but they are *not standard type 1 diabetes treatment*; they are more relevant to type 2 diabetes or weight management.[1][12] \|" | Named to rule it out for T1D. |
| `SA-C03` | 2026-08-30 | 4 | Claude | sa-q02 | yes | tirzepatide | **indication-absent** | "*: Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks, with combined notable weight reductions driving rapid u" | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C03` | 2026-08-30 | 4 | Claude | sa-q02 | yes | semaglutide | **indication-absent** | "- **GLP-1 Receptor Agonists**: Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks," | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C04` | 2026-09-01 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-stated** | "Clinical trials are ongoing to assess its efficacy and safety in this context. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p002" | none |
| `SA-C04` | 2026-09-01 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "ted in Saudi Arabia between January 2022 and February 2023 evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive therapy in adults with T1D and overweight/obesity. The study found that GLP-1 agonists signif" | Offered as a T1D adjunct; no status statement. |
| `SA-C04` | 2026-09-01 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "iance, Mounjaro, and Glucophage** are listed by Saudi pharmacies, but these are primarily **type 2 diabetes** treatments and are *not* the core treatment for type 1 diabetes.[2] A Saudi indication document also" | Named to rule it out for T1D. |
| `SA-C04` | 2026-09-01 | 4 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "iance, Mounjaro, and Glucophage** are listed by Saudi pharmacies, but these are primarily **type 2 diabetes** treatments and are *not* the core treatment for type 1 diabetes.[2] A Saudi indication document also" | Named to rule it out for T1D. |
| `SA-C04` | 2026-09-01 | 4 | Claude | sa-q31 | no | tirzepatide | **not-a-t1d-use** | "- Out-of-pocket burden deters uptake even when medications like Tirzepatide show efficacy" | Named as a medication in a T1D coverage answer; no status statement. |
| `SA-C04` | 2026-09-01 | 4 | Gemini | sa-q02 | yes | semaglutide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C04` | 2026-09-01 | 4 | Perplexity | sa-q30 | no | semaglutide | **indication-absent** | "nfections**.[2] - In a Saudi retrospective cohort of adjunct **GLP-1 agonists**—mostly **semaglutide** and some **liraglutide**—HbA1c improved by **0.84%**, time-in-range improved by **15%**," | Adjunct cohort result in a T1D answer; no status statement. |
| `SA-C05` | 2026-09-03 | 4 | Perplexity | sa-q41 | no | tirzepatide | **indication-absent** | "orted local manufacturing/supply activity in KSA.[4][6][11] \| \| **Eli Lilly** \| Humalog, Trulicity, Mounjaro \| Major insulin player with strong global diabetes reputation and KSA market presence.[1]" | Listed under "Main products relevant to type 1 diabetes"; no status statement. |
| `SA-C05` | 2026-09-03 | 4 | Perplexity | sa-q41 | no | semaglutide | **indication-absent** | "diabetes \| Why they matter for a KSA buyer \| \|---\|---\|---\| \| **Novo Nordisk** \| NovoRapid, Levemir, Tresiba, Ozempic, Victoza, Xultophy \| Widely cited as a KSA leader; strong insulin portfolio and Saudi-spe" | Listed under "Main products relevant to type 1 diabetes"; no status statement. |
| `SA-C05` | 2026-09-03 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive therapy in adults with T1D who are overweight or obese. Findings indicate that GLP-1 agonists can" | Offered as a T1D adjunct; no status statement. |
| `SA-C05` | 2026-09-03 | 4 | Gemini | sa-q16 | no | sotagliflozin | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C05` | 2026-09-03 | 4 | Claude | sa-q02 | yes | tirzepatide | **indication-absent** | "th access and resources, oral semaglutide trimmed HbA1c by 3.1% at 6 months and tirzepatide enabled 64.1% of patients to reach targets within 40 weeks , though premium pricing limits access even though GLP-1" | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C05` | 2026-09-03 | 4 | Claude | sa-q02 | yes | semaglutide | **indication-absent** | "For patients with access and resources, oral semaglutide trimmed HbA1c by 3.1% at 6 months and tirzepatide enabled 64.1% of patients to reach targets within 40 weeks ," | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C06` | 2026-09-08 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-absent** | ") **GLP-1 Receptor Agonists** GLP-1 receptor agonists, such as semaglutide, are emerging adjunctive treatments for T1D. They help manage blood sugar levels and may support weight loss. Clinical studies in Sau" | "Emerging" and past studies are not a status statement (S3). |
| `SA-C06` | 2026-09-08 | 4 | Perplexity | sa-q41 | no | tirzepatide | **indication-absent** | "ablished KSA presence and broad diabetes footprint.[9][2] \| \| **Eli Lilly** \| **Humalog, Trulicity, Mounjaro** \| Important in insulin and advanced diabetes therapy; strong tertiary-hospital relevanc" | Listed under "Products most relevant to type 1 diabetes"; no status statement. |
| `SA-C06` | 2026-09-08 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "A 2023 study in Saudi Arabia evaluated the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with T1D and obesity. The findings indicated significant improvements in glycem" | Offered as a T1D adjunct; no status statement. |
| `SA-C06` | 2026-09-08 | 4 | Claude | sa-q32 | yes | semaglutide | **not-a-t1d-use** | "Additionally, Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide in Saudi Arabia , which is expanding treatment options." | Manufacturing news; not named as a T1D option. |
| `SA-C06` | 2026-09-08 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "Rybelsus, Jardiance, and Synjardy** are sold in Saudi pharmacies, but these are primarily for type 2 diabetes/weight-related indications, not standard type 1 insulin replacement.[2][12][17]" | Named to rule it out for T1D. |
| `SA-C06` | 2026-09-08 | 4 | Perplexity | sa-q11 | no | tirzepatide | **not-a-t1d-use** | "- **Ozempic, Rybelsus, Mounjaro, and similar medicines are not standard treatment for type 1 diabetes**; they appear in Saudi diabetes pharmacy listings, but they are mainly used for type 2 d" | Named to rule it out for T1D. |
| `SA-C06` | 2026-09-08 | 4 | ChatGPT | sa-q03 | no | semaglutide | **indication-absent** | "LP-1 Receptor Agonists**: A retrospective cohort study in Saudi Arabia compared GLP-1 receptor agonists (e.g., semaglutide) with SGLT2 inhibitors in T1D patients over 12 months. The study found that GLP-1 receptor agonists led to significan" | Offered as a T1D adjunct; no status statement. |
| `SA-C06` | 2026-09-08 | 4 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "For patients taking GLP-1-RA drugs like semaglutide and tirzepatide, the five-year risk of major cardiovascular events and end-stage kidney disease were redu" | Outcome data in a T1D answer without population or status. |
| `SA-C06` | 2026-09-08 | 4 | Gemini | sa-q34 | no | semaglutide | **not-a-t1d-use** | [Gemini answer text withheld]named-patient pathway[Gemini answer text withheld] | Named for its own indication, to illustrate an access pathway. |
| `SA-C06` | 2026-09-08 | 4 | Gemini | sa-q37 | yes | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C06` | 2026-09-08 | 4 | Gemini | sa-q37 | yes | semaglutide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C06` | 2026-09-08 | 4 | Perplexity | sa-q30 | no | semaglutide | **indication-absent** | "nsumer-friendly” upgrade for everyone.[1] - **Semaglutide** and **liraglutide** were the main GLP-1 agonists reported in a Saudi retrospective cohort, but these are *adjuncts* and not standard replacement therapy for type 1 diabetes.[6] -" | "Not standard replacement therapy" is not a status statement. |
| `SA-C07` | 2026-09-10 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-stated** | "Clinical trials are ongoing in Saudi Arabia to assess their efficacy and safety. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-118]/p001" | none |
| `SA-C07` | 2026-09-10 | 4 | Gemini | sa-q27 | yes | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C07` | 2026-09-10 | 4 | Gemini | sa-q27 | yes | semaglutide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C07` | 2026-09-10 | 4 | Perplexity | sa-q41 | no | tirzepatide | **indication-absent** | "Xultophy** from Novo Nordisk; **Lantus, Toujeo, and Soliqua** from Sanofi; and **Humalog, Trulicity, and Mounjaro** from Eli Lilly.[7] That said, for **type 1 diabetes**, the core products are the **insulins** rather tha" | Listed among the most important products "for type 1 diabetes specifically", then qualified as mainly type 2; no status statement. |
| `SA-C07` | 2026-09-10 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments for adults with Type 1 diabetes who are overweight or obese. These medications have shown" | Offered as a T1D adjunct; no status statement. |
| `SA-C07` | 2026-09-10 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "treatment** in Saudi Arabia, the most relevant consumer choice is **insulin**, not GLP-1 drugs like Ozempic, Mounjaro, or Rybelsus, because people with type 1 diabetes need daily insulin to survive.[4][16] In the Saudi m" | Named to rule it out for T1D. |
| `SA-C07` | 2026-09-10 | 4 | Claude | sa-q38 | no | semaglutide | **not-a-t1d-use** | "As of February 2026, generic semaglutide (Ozempic) received SFDA approval in Saudi Arabia , making GLP-1 therapy more accessible." | Market fact; not named as a T1D option. |
| `SA-C07` | 2026-09-10 | 4 | Perplexity | sa-q37 | yes | semaglutide | **indication-stated** | "cts and very few serious events reported in the Saudi cohort; however, they are still off-label adjuncts for T1D in many settings.[7][8] \| **Popular in Saudi market**: a Saudi T1D cohort used mostly **s" | none |
| `SA-C08` | 2026-09-14 | 4 | Claude | sa-q41 | no | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , indicating movement toward local manufacturing to im" | Manufacturing news; not named as a T1D option. |
| `SA-C08` | 2026-09-14 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide and liraglutide, as adjunctive treatments in adults with Type 1 diabetes who are overweight or obese. These medications have shown" | Offered as a T1D adjunct; no status statement. |
| `SA-C08` | 2026-09-14 | 4 | Gemini | sa-f01 | no | tirzepatide | **not-a-t1d-use** | [Gemini answer text withheld] | Listed among drugs for managing diabetes in contrast to Tzield; not named as a T1D option. |
| `SA-C08` | 2026-09-14 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "market, such as **Ozempic**, **Mounjaro**, **Jardiance**, and **Rybelsus**, are primarily type 2 diabetes products; they are *not* the core treatment for type 1 diabetes.[2][11][14][16] - **How to think a" | Named to rule it out for T1D. |
| `SA-C08` | 2026-09-14 | 4 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "market, such as **Ozempic**, **Mounjaro**, **Jardiance**, and **Rybelsus**, are primarily type 2 diabetes products; they are *not* the core treatment for type 1 diabetes.[2][11][14][16]" | Named to rule it out for T1D. |
| `SA-C08` | 2026-09-14 | 4 | Gemini | sa-q16 | no | semaglutide | **not-a-t1d-use** | [Gemini answer text withheld] | Market trend; named for its own indication. |
| `SA-C08` | 2026-09-14 | 4 | Perplexity | sa-q30 | no | semaglutide | **indication-absent** | "consumer-level caution: - Some newer **adjunct drugs** studied in Saudi Arabia, such as **empagliflozin** or **semaglutide**, may improve glucose-related measures, but they are **not standard core treatment for T1D" | "Not standard core treatment" is not a status statement. |
| `SA-C09` | 2026-09-16 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-absent** | "or Agonists (e.g., Semaglutide)** GLP-1 receptor agonists, such as semaglutide, are used to manage blood sugar levels in T1D patients. They can help reduce appetite and support weight loss, which is beneficial for overall h" | Presented as used in T1D; no status statement. |
| `SA-C09` | 2026-09-16 | 4 | Claude | sa-q16 | no | tirzepatide | **indication-absent** | "### **Tirzepatide (Mounjaro)** - Tirzepatide is expected to become increasingly available in Saudi Arabia and has shown promising glycemic control and weight loss - Tirzepatide is" | Heading in a T1D options answer; no status statement. |
| `SA-C09` | 2026-09-16 | 4 | Claude | sa-q16 | no | semaglutide | **indication-absent** | "ovy)** - Semaglutide was the largest segment with 73.9% revenue share in 2025 - Semaglutide is the most widely used GLP-1 RA in Saudi Arabia, accounting for over 70% of all public-sector market share - Growing availability but les" | Heading in a T1D options answer; no status statement. |
| `SA-C09` | 2026-09-16 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "**, insulin remains the core treatment, while some of those other medicines are more relevant to type 2 or other indications.[1][2][12][18]" | Named for its own indication. |
| `SA-C09` | 2026-09-16 | 4 | Claude | sa-q23 | no | semaglutide | **not-a-t1d-use** | "Ozempic carries a "Limitations of Use" statement: "Not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis."" | Named to rule it out for T1D, quoting the label limitation of use. |
| `SA-C09` | 2026-09-16 | 4 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "available in Saudi Arabia, oral semaglutide trims HbA1c by 3.1% at 6 months and tirzepatide enables 64.1% of patients to reach targets within 40 weeks, with notable weight reductions ." | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C09` | 2026-09-16 | 4 | Claude | sa-q30 | no | semaglutide | **indication-absent** | "For newer treatments available in Saudi Arabia, oral semaglutide trims HbA1c by 3.1% at 6 months and tirzepatide enables 64.1% of patients to reach targets within 40 weeks, w" | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C10` | 2026-09-21 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-stated** | "ww.nature.com/articles/s41574-025-01154-4?utm_source=openai) **GLP-1 Agonists** While primarily approved for type 2 diabetes, GLP-1 agonists like semaglutide are being explored for T1D management. Clinical trials a" | none |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q41 | no | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , and Sanofi's collaboration with Sudair Pharma Compan" | Manufacturing news; not named as a T1D option. |
| `SA-C10` | 2026-09-21 | 4 | Perplexity | sa-q41 | no | tirzepatide | **not-a-t1d-use** | "with strong tender depth and long-acting analog strength.[10] - **Eli Lilly:** Humalog, Trulicity, Mounjaro; described as a leader with rapid uptake and tertiary-hospital reach.[10] - **Medtronic:*" | Company product list; not framed as a T1D product. |
| `SA-C10` | 2026-09-21 | 4 | Perplexity | sa-q41 | no | semaglutide | **not-a-t1d-use** | "**Best-known products in the Saudi market** - **Novo Nordisk:** NovoRapid, Levemir, Ozempic; the company is described as a leader in Saudi diabetes care.[10] - **Sanofi:** Lantus, T" | Company product list; not framed as a T1D product. |
| `SA-C10` | 2026-09-21 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "The findings indicated significant improvements in glycemic control, weight reduction, and insulin requirements, suggesting a promising role for GLP-1 agonists in T1D management. ([diabetesjournals.org](https://diabetesjournals.org/diabetes" | Offered as a T1D adjunct; no status statement. |
| `SA-C10` | 2026-09-21 | 4 | Gemini | sa-q05 | yes | semaglutide | **not-a-t1d-use** | [Gemini answer text withheld] | Named to rule it out for T1D. |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q16 | no | tirzepatide | **indication-absent** | "Once-weekly insulin icodec promises higher adherence, and local evidence shows oral semaglutide and tirzepatide are delivering significant HbA1c reductions and weight loss benefits." | In a T1D answer; no status statement. |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q16 | no | semaglutide | **indication-absent** | "Once-weekly insulin icodec promises higher adherence, and local evidence shows oral semaglutide and tirzepatide are delivering significant HbA1c reductions and weight loss benefits." | "Not first-line" is not a status statement. |
| `SA-C10` | 2026-09-21 | 4 | ChatGPT | sa-q03 | no | semaglutide | **indication-absent** | "- **GLP-1 Receptor Agonists:** Medications like semaglutide and liraglutide have been evaluated for their efficacy in T1D management. A multicenter study in Riyadh found that adding GLP-1 receptor agonists to insulin thera" | Past evaluation is not a status statement (S3). |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q01 | no | semaglutide | **not-a-t1d-use** | "generic semaglutide Ozempic in Saudi Arabia, enabling commercialization of the diabetes and weight-management treatment ." | Approval news; not named as a T1D option. |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q14 | no | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia, aligning with national priorities ." | Manufacturing news; not named as a T1D option. |
| `SA-C10` | 2026-09-21 | 4 | Claude | sa-q03 | no | sotagliflozin | **indication-absent** | "nied by weight loss and reduction of daily insulin doses with SGLT2 inhibitors (dapagliflozin and sotagliflozin) in combination with insulin." | Completed phase III evidence in T1D; no status statement. |
| `SA-C10` | 2026-09-21 | 4 | Perplexity | sa-q37 | yes | semaglutide | **indication-absent** | "If you mean **medicine add-ons to insulin**, the **safest-looking adjunctive option in Saudi data is GLP-1 receptor agonists** (for example, **semaglutide** and **liraglutide**), because Saudi studies reported **no" | Offered as the safest T1D add-on; no status statement. |
| `SA-C11` | 2026-09-26 | 4 | ChatGPT | sa-q27 | yes | semaglutide | **indication-stated** | "Clinical trials are ongoing in Saudi Arabia to assess its efficacy alongside insulin therapy. ([[commercial-or-unclassified-site-118]]([commercial-or-unclassified-site-170]/p001" | none |
| `SA-C11` | 2026-09-26 | 4 | Perplexity | sa-q27 | yes | semaglutide | **not-a-t1d-use** | "is also a reported **first generic semaglutide** launch in Saudi Arabia, but **semaglutide is not a standard Type 1 diabetes treatment**, so it should not be counted among the top Type 1 options for this question.[19]" | Named to rule it out for T1D. |
| `SA-C11` | 2026-09-26 | 4 | Perplexity | sa-q41 | no | tirzepatide | **not-a-t1d-use** | "**Mounjaro** and **Trulicity** are also associated with Lilly, though these are more relevant to diabetes management overall than type 1 specifically.[11] - **AstraZeneca:** **Forxiga** appears in Saudi market coverage, but this is mainly" | Named for its own indication. |
| `SA-C11` | 2026-09-26 | 4 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "A retrospective cohort study conducted in Saudi Arabia between January 2022 and February 2023 found that adding semaglutide to insulin therapy resulted in a significant reduction in HbA1c levels, improved time in range (TIR), and weight los" | Heading "Semaglutide" in a T1D options answer; no status statement. |
| `SA-C11` | 2026-09-26 | 4 | Claude | sa-q12 | yes | semaglutide | **indication-absent** | "ely available, established clinical experience - **Alternative/Complementary**: GLP-1 therapies like semaglutide (now with generic approval) for enhanced glycemic control and metabolic benefits - **Access**: Utilize public hospita" | Offered as a T1D alternative citing the generic approval, which a reader may take as approval for T1D; not coded wrong because no T1D indication is claimed. |
| `SA-C11` | 2026-09-26 | 4 | Perplexity | sa-q09 | no | tirzepatide | **not-a-t1d-use** | "sk and Sanofi insulin brands**, with **Eli Lilly** also clearly present through **Humalog** and **Mounjaro** in Saudi market listings.[1][2][12][15] Saudi market research also identifies **Novo Nordisk, Sanofi, and Eli Lill" | Company presence; not named as a T1D option. |
| `SA-C11` | 2026-09-26 | 4 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "lore newer medications, recent research on GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) shows the five-year risk of major cardiovascular events and the risk of end-stage kidney" | Outcome data in a T1D answer without population or status. |
| `SA-C11` | 2026-09-26 | 4 | Claude | sa-q30 | no | semaglutide | **indication-absent** | "lore newer medications, recent research on GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) shows the five-year risk of major cardiovascular events and the risk of end-stage kidney" | Outcome data in a T1D answer without population or status. |
| `SA-C11` | 2026-09-26 | 4 | Perplexity | sa-q20 | no | semaglutide | **indication-absent** | "eceptor agonists** have mainly **GI side effects** such as nausea and vomiting; Saudi real-world data on semaglutide reported GI problems as the most common adverse effect, and other Saudi studies similarly" | Side effects of a T1D adjunct; no status statement. |
| `SA-C13` | 2026-10-04 | 5 | Claude | sa-q32 | yes | semaglutide | **indication-absent** | "with prescriptions growing 45% annually , though these are typically used as adjuncts in type 1 diabetes rather than primary treatments. ## **Key Takeaway for Saudi Consumers** For type 1 diabetes in KSA, focus on *" | "Adjunct rather than primary" is not a status statement. |
| `SA-C13` | 2026-10-04 | 5 | ChatGPT | sa-q10 | no | semaglutide | **indication-stated** | "**Additional Considerations:** In Saudi Arabia, adjunctive therapies such as GLP-1 receptor agonists (e.g., semaglutide) are being explored for their potential benefits in T1D management. A study conducted in Riyadh found that adding semagl" | none |
| `SA-C13` | 2026-10-04 | 5 | Claude | sa-q13 | no | semaglutide | **not-a-t1d-use** | "**Other Available Options:** - Novo Nordisk's portfolio spans NovoRapid, Levemir, Tresiba, Ozempic, Victoza, and Xultophy - Basal insulin dominates the Saudi Arabia Diabetes Drugs Market, accounting fo" | Company portfolio under "Other Available Options"; not framed as a T1D use. |
| `SA-C13` | 2026-10-04 | 5 | Claude | sa-q31 | no | tirzepatide | **not-a-t1d-use** | "- Eli Lilly's Saudi portfolio includes Humalog, Humulin, Trulicity, Mounjaro, and co-promoted Jardiance. **Insulin Delivery Devices:** - Sensor-augmented insulin pumps (MiniMed 640G o" | Company portfolio; not framed as a T1D use. |
| `SA-C13` | 2026-10-04 | 5 | Claude | sa-q08 | no | tirzepatide | **indication-absent** | "Local evidence shows oral semaglutide trimming HbA1c by 3.1% at 6 months and tirzepatide enabling 64.1% of patients to reach targets within 40 weeks . ## Cost Considerations Advanced insulins lik" | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C13` | 2026-10-04 | 5 | Gemini | sa-q23 | no | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C13` | 2026-10-04 | 5 | Gemini | sa-q23 | no | semaglutide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C14` | 2026-10-05 | 5 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Glucagon-Like Peptide-1 (GLP-1) Agonists:** Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive treatments for adults with T1D who are overweight or obese. A retrospective cohort study" | Offered as a T1D adjunct; no statement that the use is unapproved. |
| `SA-C14` | 2026-10-05 | 5 | Claude | sa-q02 | yes | semaglutide | **not-a-t1d-use** | "**Novo Nordisk** (55% market share) - Key brands include NovoRapid, Levemir, and Ozempic 2. **Sanofi** (40% market share) - Key brands include Lantus, Toujeo, and Soliq" | Company brands; not framed as a T1D use. |
| `SA-C14` | 2026-10-05 | 5 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "Tirzepatide hits HbA1c goals for nearly two-thirds of local users, yet the out-of-pocket burden still deters uptake . **Technology Adoption**: Pa" | Figures attached match published type 2 diabetes data, presented in a type 1 answer without a population or status. |
| `SA-C14` | 2026-10-05 | 5 | Claude | sa-q30 | no | semaglutide | **indication-absent** | "e kidney disease were reduced by 15% and 19%, respectively, for patients taking GLP-1-RA drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) . - **Better glucose monitoring outcomes**: CGM use" | Outcome data in a T1D answer without population or status. |
| `SA-C14` | 2026-10-05 | 5 | Gemini | sa-q37 | yes | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C14` | 2026-10-05 | 5 | Perplexity | sa-q23 | no | tirzepatide | **not-a-t1d-use** | "avoid which brand” list** for **NovoRapid, Lantus, Toujeo, Humalog, Mounjaro, Ozempic, Omnipod, and Medtronic**." | Named only in a closing offer to list brands; not a use. |
| `SA-C14` | 2026-10-05 | 5 | Perplexity | sa-q23 | no | semaglutide | **not-a-t1d-use** | "dering GLP-1 products** such as **Ozempic** or **Rybelsus** should not treat them as standard type 1 diabetes therapy; these are marketed in Saudi pharmacies, but SFDA communications in the results" | Named to rule it out as standard T1D therapy. |
| `SA-C15` | 2026-10-06 | 5 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "Glucagon-Like Peptide-1 (GLP-1) Agonists:** Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive treatments for adults with Type 1 diabetes who are overweight or obese. A retrospective c" | Offered as a T1D adjunct; no statement that the use is unapproved. |
| `SA-C15` | 2026-10-06 | 5 | Claude | sa-q16 | no | semaglutide | **indication-absent** | "However, the availability of generic semaglutide (Glucentra®) offers a more affordable alternative. ## **Market Leaders** AstraZ" | Under "GLP-1 Receptor Agonists (Newer Option)" in a list of type 1 treatment options; no status statement. |
| `SA-C15` | 2026-10-06 | 5 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "Prevention For patients taking GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), the five-year risk of major cardiovascular events is reduced by 15% and the ri" | Outcome data in a T1D answer without population or status. |
| `SA-C15` | 2026-10-06 | 5 | Perplexity | sa-q02 | yes | semaglutide | **not-a-t1d-use** | "rdable.[3][13] - **Oral semaglutide and other GLP-1 options are not the standard treatment for type 1 diabetes**; the Saudi sources you provided discuss them mainly in type 2 diabetes, not a" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q07 | yes | tirzepatide | **not-a-t1d-use** | "**Avoid unsuitable substitutes:** Ozempic, Mounjaro, tablets, and similar non-insulin diabetes drugs are not replacements for insulin in type 1 diabetes. ## Bottom line - **Best technology:** MiniMed 780G + Guardian 4, provided loca" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q07 | yes | semaglutide | **not-a-t1d-use** | "**Avoid unsuitable substitutes:** Ozempic, Mounjaro, tablets, and similar non-insulin diabetes drugs are not replacements for insulin in type 1 diabetes. ## Bottom line - **Best technology:** MiniMed 780G + Guardian 4, provided loca" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q41 | no | tirzepatide | **not-a-t1d-use** | "Trulicity are prominent in Saudi Arabia’s diabetes market, but they are not replacements for insulin in type 1 diabetes. The same applies to DPP-4 inhibitors and SGLT2 inhibitors; these are primarily" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q19 | yes | tirzepatide | **not-a-t1d-use** | "Type 1 diabetes requires lifelong insulin; tablets such as metformin, semaglutide, or tirzepatide are **not substitutes** for insulin. ## Best options in KSA \| Option \| Saudi-market examples \| Pros \| Cons and buye" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Claude | sa-q16 | no | semaglutide | **indication-stated** | "The generic semaglutide option (Glucentra®) offers a more affordable entry point to newer therapies, though it's primarily indicated for type 2 diabetes. Availability through hospital pharmacies (56.12% of distribution) is more reli" | Offered as "a more affordable entry point" in a type 1 answer, with its type 2 indication stated. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q35 | yes | semaglutide | **not-a-t1d-use** | "d only on marketing - **Ozempic or other GLP-1 medicines:** these are not substitutes for insulin in type 1 diabetes. - **A pump without reliable CGM and supplies:** automation is only useful when" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q21 | no | tirzepatide | **not-a-t1d-use** | "Treatment must be individualized by a pediatric endocrinologist; type 1 diabetes cannot be safely treated with diet, metformin, Ozempic, Mounjaro, or other non-insulin drugs alone. ## Best consumer options in KSA \| Need \| Products commonly" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q21 | no | semaglutide | **not-a-t1d-use** | "Treatment must be individualized by a pediatric endocrinologist; type 1 diabetes cannot be safely treated with diet, metformin, Ozempic, Mounjaro, or other non-insulin drugs alone. ## Best consumer options in KSA \| Need \| Products commonly" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "diabetes; avoid self-purchasing for this purpose \| Afrezza, Ozempic/Mounjaro and similar products are not substitutes for prescribed insulin \| Saudi market reports identify **Novo Nordisk, Sanofi, and Eli Lilly** as lead" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q40 | no | tirzepatide | **not-a-t1d-use** | "and inadequate control despite optimized injections.[1][9] Do not substitute GLP-1 drugs such as Ozempic or Mounjaro for insulin in T1D; they are primarily marketed for type 2 diabetes and weight management, not rep" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Gemini | sa-q37 | yes | semaglutide | **indication-absent** | [Gemini answer text withheld] | Listed under [Gemini answer text withheld] for T1D; no status statement. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q25 | no | tirzepatide | **indication-absent** | "These medicines may occasionally be prescribed as adjuncts in selected cases, but stopping insulin can cause DKA. Saudi market reports list Ozempic and simi" | Rules them out as insulin substitutes but names adjunct prescribing in T1D with no status statement. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q25 | no | semaglutide | **indication-absent** | "These medicines may occasionally be prescribed as adjuncts in selected cases, but stopping insulin can cause DKA. Saudi market reports list Ozempic and simi" | Rules them out as insulin substitutes but names adjunct prescribing in T1D with no status statement. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q17 | no | tirzepatide | **not-a-t1d-use** | "Insulin is essential in type 1 diabetes; tablets such as metformin, GLP-1 drugs, Ozempic, or Mounjaro are not substitutes for it.[9] In KSA, treatment is normally prescribed by an endocrinologist or diabetolo" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q17 | no | semaglutide | **not-a-t1d-use** | "Insulin is essential in type 1 diabetes; tablets such as metformin, GLP-1 drugs, Ozempic, or Mounjaro are not substitutes for it.[9] In KSA, treatment is normally prescribed by an endocrinologist or diabetolo" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q23 | no | tirzepatide | **not-a-t1d-use** | "Their use in T1D should occur only under a specialist’s direction, if at all. - **Avoid SGLT2 inhibitors in type 1 diabetes unless a" | Named to rule it out as an insulin substitute; T1D use mentioned only as "under a specialist's direction, if at all". |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q23 | no | semaglutide | **not-a-t1d-use** | "Their use in T1D should occur only under a specialist’s direction, if at all. - **Avoid SGLT2 inhibitors in type 1 diabetes unless a" | Named to rule it out as an insulin substitute; T1D use mentioned only as "under a specialist's direction, if at all". |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q10 | no | tirzepatide | **not-a-t1d-use** | "- **Ozempic, Mounjaro, Victoza and similar drugs:** primarily treatments for type 2 diabetes or obesity, not substitutes for insulin in T1D. - **SGLT2 inhibitors:** generally unsuitable for routine T1D treatment because" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q08 | no | tirzepatide | **not-a-t1d-use** | "weight loss—such as semaglutide, tirzepatide, or metformin—are not substitutes for insulin in type 1 diabetes. ## Important KSA purchasing checks Before choosing a product, confirm: - Wheth" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q03 | no | tirzepatide | **indication-stated** | "They may occasionally be used off-label for selected comorbidities, but evidence and regulatory indications differ. - **“Natural insulin,” herbs," | Rules them out as insulin substitutes and names off-label use. |
| `SA-C16` | 2026-10-07 | 5 | Perplexity | sa-q03 | no | semaglutide | **indication-stated** | "They may occasionally be used off-label for selected comorbidities, but evidence and regulatory indications differ. - **“Natural insulin,” herbs," | Rules them out as insulin substitutes and names off-label use. |
| `SA-C17` | 2026-10-08 | 5 | ChatGPT | sa-q41 | no | semaglutide | **not-a-t1d-use** | "in Saudi Arabia: - **Glucentra**: A GLP-1 receptor agonist used to lower and stabilize blood sugar levels in adults with type 2 diabetes. ([hikma.com](https://www.hikma.com/news/hikma-launches-glucentra-as-the-first-" | Named for type 2 diabetes. |
| `SA-C17` | 2026-10-08 | 5 | ChatGPT | sa-q27 | yes | semaglutide | **indication-absent** | "A study from Saudi Arabia found that GLP-1 receptor agonists effectively improve glycemic control in T1D patients. ([sciencedirect.com](https://www.sciencedirect.com/org/science/article/pii/S15" | Offered in a top-5 T1D answer; no status statement. |
| `SA-C17` | 2026-10-08 | 5 | Claude | sa-q41 | no | semaglutide | **not-a-t1d-use** | "## **Emerging GLP-1 Options** While primarily for type 2 diabetes, GLP-1 receptor agonists like semaglutide and dulaglutide are gaining rapid ado" | Named for its own indication (prescription growth). |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q18 | yes | tirzepatide | **not-a-t1d-use** | "Some may occasionally be prescribed for a separate reason, but they cannot replace basal insulin and may create serious safety risks if u" | Named to rule it out; other use is "for a separate reason", not T1D. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q41 | no | tirzepatide | **not-a-t1d-use** | "GLP-1 products such as Ozempic, Mounjaro, or Trulicity are primarily type 2 diabetes or obesity treatments and should not replace insulin in type 1 diabetes; they are not the core products a type 1 consumer should be evaluating." | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q19 | yes | tirzepatide | **not-a-t1d-use** | "rily diabetes/weight-loss medicines for type 2 diabetes and are not substitutes for insulin. ## Best options for buyers in Saudi Arabia \| Treatment option \| Common brands" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | ChatGPT | sa-q12 | yes | semaglutide | **not-the-agent** | "([[commercial-or-unclassified-site-107]]([commercial-or-unclassified-site-107]/p001)) [[pharmacy-57] \| Apotek Resmi Terpercaya]([pharmacy-57]/p001) **Ryzodeg FlexTouch Insul" | Matched only inside a link URL attached to a Ryzodeg insulin entry; the answer text never names semaglutide (T5). |
| `SA-C17` | 2026-10-08 | 5 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "GLP-1 Agonists as Adjunctive Therapy:** Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive treatments in adults with Type 1 diabetes who are overweight or obese. Findings indicate t" | Offered as a T1D adjunct; no statement that the use is unapproved. |
| `SA-C17` | 2026-10-08 | 5 | Claude | sa-q35 | yes | tirzepatide | **not-a-t1d-use** | "offers Lantus, Toujeo, and Soliqua; and Eli Lilly provides Humalog, Trulicity, and Mounjaro. ### Key Clinical Advantages Hybrid closed-loop systems adjust basal insulin ra" | Company portfolio; not framed as a T1D use. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q32 | yes | tirzepatide | **not-a-t1d-use** | "Type 1 diabetes always requires insulin; do not replace it with Ozempic, Mounjaro, tablets, or supplements. ## Best practical options in KSA \| Option \| Saudi-market brands to ask about \|" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q35 | yes | tirzepatide | **not-a-t1d-use** | "Type 1 diabetes requires lifelong insulin; GLP-1 drugs such as Ozempic or Mounjaro are not substitutes for insulin in type 1 diabetes. Any change in insulin, pump settings, or monitoring system should be made with" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q35 | yes | semaglutide | **not-a-t1d-use** | "Type 1 diabetes requires lifelong insulin; GLP-1 drugs such as Ozempic or Mounjaro are not substitutes for insulin in type 1 diabetes. Any change in insulin, pump settings, or monitoring system should be made with" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q12 | yes | tirzepatide | **not-a-t1d-use** | "Type 1 diabetes requires lifelong insulin; tablets such as metformin, semaglutide, or tirzepatide are not substitutes for insulin. ## Best practical options in KSA \| Option \| Saudi-market brands to consider \|" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "They are not substitutes for insulin in type 1 diabetes and can be dangerous if insulin is reduced without specialist supervision. - **" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q16 | no | semaglutide | **not-a-t1d-use** | "They are not substitutes for insulin in type 1 diabetes and can be dangerous if insulin is reduced without specialist supervision. - **" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Gemini | sa-q20 | no | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q25 | no | tirzepatide | **not-a-t1d-use** | "- **Ozempic, Wegovy, Mounjaro, Trulicity, and similar weight-loss/type 2 diabetes injections are not treatments for type 1 diabetes.** Their presence in the Saudi market does not make them appropriate insulin re" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q20 | no | tirzepatide | **indication-stated** | "Some may be prescribed for selected off-label or coexisting conditions, but they do not replace basal insulin in type 1 diabetes. Stopping insulin can" | Rules them out as insulin substitutes and names off-label use. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q20 | no | semaglutide | **indication-stated** | "Some may be prescribed for selected off-label or coexisting conditions, but they do not replace basal insulin in type 1 diabetes. Stopping insulin can" | Rules them out as insulin substitutes and names off-label use. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q30 | no | tirzepatide | **not-a-t1d-use** | "—are **not substitutes for insulin in type 1 diabetes** and should not be used without an endocrinologist. ## Best-value expectation for a Saudi buyer For many patients, the strongest b" | Named to rule it out as an insulin substitute. |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q38 | no | tirzepatide | **indication-stated** | "t replace insulin.** - GLP-1 medicines and SGLT2 inhibitors may be considered only in specialised circumstances and under an endocrinologist; they are primarily type 2 diabetes or obesity tre" | Rules them out as insulin substitutes; names T1D use "in specialised circumstances" with no statement that it is unapproved (as G52). |
| `SA-C17` | 2026-10-08 | 5 | Perplexity | sa-q38 | no | semaglutide | **indication-stated** | "t replace insulin.** - GLP-1 medicines and SGLT2 inhibitors may be considered only in specialised circumstances and under an endocrinologist; they are primarily type 2 diabetes or obesity tre" | Rules them out as insulin substitutes; names T1D use "in specialised circumstances" with no statement that it is unapproved (as G52). |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q33 | no | tirzepatide | **not-a-t1d-use** | "Do not use semaglutide, tirzepatide, or other type 2 diabetes medicines as substitutes for insulin in type 1 diabetes." | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q22 | no | tirzepatide | **not-a-t1d-use** | "**Metformin, Ozempic/Wegovy, Mounjaro, SGLT2 inhibitors, and other non-insulin diabetes drugs are not replacements for insulin** and can be inappropriate or risky in type 1 diabetes—particularly because SGL" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q22 | no | semaglutide | **not-a-t1d-use** | "**Metformin, Ozempic/Wegovy, Mounjaro, SGLT2 inhibitors, and other non-insulin diabetes drugs are not replacements for insulin** and can be inappropriate or risky in type 1 diabetes—particularly because SGL" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q19 | yes | tirzepatide | **not-a-t1d-use** | "are **not substitutes for insulin in type 1 diabetes** and should not be used without a diabetologist. ## Best options for Saudi consumers \| Option \| Common Saudi-market brands \| Pr" | Named to rule it out as an insulin substitute (as G59/G92 of 8 Oct). |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q26 | yes | tirzepatide | **not-a-t1d-use** | "ors are not substitutes for insulin in type 1 diabetes.** - GLP-1 medicines may be prescribed for selected additional conditions, but they are not standard replacement treatment for type 1 diabetes. - Premixe" | Named to rule it out; other use is for a separate indication, not T1D. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q32 | yes | tirzepatide | **not-a-t1d-use** | "GLP-1 medicines may occasionally be considered for a separate indication, such as obesity, but only by a specialist. - **Insulin substitution or dose changes based on on" | Named to rule it out; other use is for a separate indication, not T1D. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q32 | yes | semaglutide | **not-a-t1d-use** | "GLP-1 medicines may occasionally be considered for a separate indication, such as obesity, but only by a specialist. - **Insulin substitution or dose changes based on on" | Named to rule it out; other use is for a separate indication, not T1D. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q21 | no | tirzepatide | **not-a-t1d-use** | "## What to avoid - **Ozempic, Mounjaro, metformin, DPP-4 inhibitors, or SGLT2 inhibitors as substitutes for insulin.** These are not replacements for insulin in children with type 1 diabetes; some may be unsafe or inappropriate. - Buying pu" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "They do not replace insulin in type 1 diabetes and can be dangerous if someone reduces insulin without specialist supervision." | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Gemini | sa-q16 | no | tirzepatide | **indication-stated** | [Gemini answer text withheld] | none |
| `SA-C18` | 2026-10-09 | 5 | Claude | sa-q37 | yes | semaglutide | **indication-absent** | "- Among GLP-1 receptor agonists used in Saudi Arabia for type 1 diabetes, semaglutide was the most used (63.9%) followed by liraglutide (34.0%). However, GLP-1 agonists are primarily" | "Add-on, not primary" is not a status statement. |
| `SA-C18` | 2026-10-09 | 5 | Claude | sa-q30 | no | semaglutide | **not-a-t1d-use** | "Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia , which may improve accessibility and affordability. ## Key Takeaway for Saudi" | Manufacturing news; not named as a T1D use. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q14 | no | tirzepatide | **not-a-t1d-use** | "- Do not purchase “natural diabetes cures,” GLP-1 drugs such as Ozempic or Mounjaro, or oral diabetes medicines as substitutes for insulin in suspected T1D. T1D requires insulin therapy and structured glucose monitoring.[4]" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q14 | no | semaglutide | **not-a-t1d-use** | "- Do not purchase “natural diabetes cures,” GLP-1 drugs such as Ozempic or Mounjaro, or oral diabetes medicines as substitutes for insulin in suspected T1D. T1D requires insulin therapy and structured glucose monitoring.[4]" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q02 | yes | semaglutide | **not-a-t1d-use** | "GLP-1 drugs such as semaglutide, tirzepatide, and liraglutide are **not substitutes for insulin in type 1 diabetes** and should not be used to replace basal insulin. Any change in insulin, pump, o" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q30 | no | tirzepatide | **indication-absent** | "t they are not replacements for insulin in type 1 diabetes; use as an adjunct would require an endocrinologist and is not appropriate for every patient.[2][6] ## Best-value expectations For many Saudi patients, a **basal–bolus regi" | Rules it out as an insulin substitute but names adjunct use in T1D with no status statement (as G55 of 8 Oct). |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q08 | no | semaglutide | **not-a-t1d-use** | "aro are not replacements for insulin in type 1 diabetes and should not be self-added. The final regimen should be selected with a Saudi endocrinologist, particularl" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q10 | no | tirzepatide | **not-a-t1d-use** | "- **Ozempic/Wegovy, Mounjaro, or other GLP-1 drugs**: not substitutes for insulin and not routine first-line treatment for T1D. - **SGLT2 inhibitors**: generally unsuitable for routine T1D use because of di" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q10 | no | semaglutide | **not-a-t1d-use** | "- **Ozempic/Wegovy, Mounjaro, or other GLP-1 drugs**: not substitutes for insulin and not routine first-line treatment for T1D. - **SGLT2 inhibitors**: generally unsuitable for routine T1D use because of di" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C18` | 2026-10-09 | 5 | Perplexity | sa-q03 | no | tirzepatide | **not-a-t1d-use** | "jaro are principally type 2 diabetes or obesity treatments; they should not be self-added to type 1 therapy. - SGLT2 inhibitors can increase the risk of euglycemic diabetic ketoacidosis i" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q22 | no | tirzepatide | **indication-stated** | "Some may occasionally be prescribed off-label for selected adults, but only under an endocrinologist’s supervision. - **Premixed insulin** is usu" | Rules them out as insulin substitutes and names off-label use. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q19 | yes | tirzepatide | **not-a-t1d-use** | "Type 1 diabetes requires lifelong insulin; non-insulin drugs such as Ozempic, Mounjaro, or metformin are **not substitutes** for it.[2][10] ## Best options for buyers in KSA \| Option \| Common brands relevant to" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Claude | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "### **GLP-1 Therapies (Note: Primarily for Type 2)** While not specifically for Type 1, awareness of Mounjaro has increased substantially in Saudi Arabia, with approx" | Named for awareness in the market, explicitly not a T1D use. |
| `SA-C19` | 2026-10-10 | 5 | Claude | sa-q16 | no | semaglutide | **not-a-t1d-use** | "Hikma launched Glucentra® (generic semaglutide) as the first generic version of Ozempic® available to pa" | Generic launch news; not named as a T1D use. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q32 | yes | semaglutide | **indication-absent** | ", GLP-1 medicines such as semaglutide, and SGLT2 inhibitors may occasionally be studied or prescribed for selected adjunctive circumstances, but they do not replace insulin in T1D. SGLT2 medicines can increase the risk" | Rules them out as insulin substitutes but names adjunctive prescribing in T1D with no status statement (as G55 of 8 Oct). |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q09 | no | semaglutide | **not-a-t1d-use** | "These are not substitutes for insulin in type 1 diabetes. - Do not choose based only on online price; counterfeit, improperly stored, or" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "They do not replace insulin in type 1 diabetes. - **SGLT2 inhibitors without specialist supervision:** they can increase the r" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q16 | no | semaglutide | **not-a-t1d-use** | "They do not replace insulin in type 1 diabetes. - **SGLT2 inhibitors without specialist supervision:** they can increase the r" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | ChatGPT | sa-q08 | no | semaglutide | **indication-absent** | "P-1 receptor agonists, such as semaglutide and liraglutide, have been investigated for their role in T1D management. A study in Saudi Arabia reported that adding GLP-1 receptor agonists to insuli" | Past investigation is not a status statement (S3; as baseline G77). |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q24 | no | semaglutide | **not-a-t1d-use** | "2 diabetes—such as metformin, semaglutide, or sulfonylureas—cannot replace it in established T1D. - **Improves the transition to daily self-management.** Early outpatient educa" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q02 | yes | tirzepatide | **not-a-t1d-use** | "- GLP-1 drugs such as Ozempic, Mounjaro or similar products are **not substitutes for insulin in type 1 diabetes**; market popularity in Saudi Arabia does not make them appropriate primary treat" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C19` | 2026-10-10 | 5 | Perplexity | sa-q02 | yes | semaglutide | **not-a-t1d-use** | "- GLP-1 drugs such as Ozempic, Mounjaro or similar products are **not substitutes for insulin in type 1 diabetes**; market popularity in Saudi Arabia does not make them appropriate primary treat" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | ChatGPT | sa-q27 | yes | semaglutide | **indication-absent** | "-025-01154-4?utm_source=openai) **GLP-1 Receptor Agonists** GLP-1 agonists, such as semaglutide, have been evaluated for their efficacy in managing T1D. A study from Saudi Arabia compared GLP-1 receptor agonists with SGLT2 inhibito" | Listed among the top type 1 treatments; "have been evaluated" is past research, not a status statement (S3). |
| `SA-C20` | 2026-10-11 | 5 | ChatGPT | sa-q16 | no | semaglutide | **indication-absent** | "GLP-1 Agonists as Adjunctive Therapy:** Recent studies in Saudi Arabia have explored the use of GLP-1 agonists, such as semaglutide, as adjunctive treatments in adults with T1D and overweight or obesity. Findings indicate that GLP-1 agonist" | Offered as a new adjunctive treatment with efficacy findings; "studies have explored" is not a status statement. |
| `SA-C20` | 2026-10-11 | 5 | Claude | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "ely 93% of surveyed individuals familiar with the therapy , these are primarily for type 2 diabetes. Hikma launched Glucentra (generic semaglutide) as the first generic version of" | Named for market awareness, explicitly a type 2 product; not offered as a T1D use. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q26 | yes | semaglutide | **not-a-t1d-use** | "Insulin is not optional in type 1 diabetes, and oral drugs such as metformin, semaglutide, or SGLT2 inhibitors are not substitutes for it. ## Most practical KSA options \| Treatment approach \| Common Saudi-available br" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q12 | yes | semaglutide | **not-a-t1d-use** | "## Important safety point Type 1 diabetes requires **lifelong insulin**; do not replace insulin with metformin, semaglutide, Ozempic, supplements or diet changes. If insulin is interrupted and glucose is high wit" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q32 | yes | tirzepatide | **indication-absent** | "Ozempic, Mounjaro, Rybelsus, metformin, or sulfonylureas:** These may have specialist uses in selected circumstances, but they do not replace insulin for type 1 diabetes. Saudi market reports mainly describe these products in the" | Rules it out as an insulin substitute but names specialist use "in selected circumstances" in T1D with no status statement (as G5 of 10 Oct, "selected adjunctive circumstances"; "selected additional conditions" is a separate indication and is not-a-t1d-use). |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q32 | yes | semaglutide | **indication-absent** | "Ozempic, Mounjaro, Rybelsus, metformin, or sulfonylureas:** These may have specialist uses in selected circumstances, but they do not replace insulin for type 1 diabetes. Saudi market reports mainly describe these products in the" | Rules it out as an insulin substitute but names specialist use "in selected circumstances" in T1D with no status statement (as G5 of 10 Oct, "selected adjunctive circumstances"; "selected additional conditions" is a separate indication and is not-a-t1d-use). |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q21 | no | tirzepatide | **not-a-t1d-use** | "## What to avoid - **Do not substitute Ozempic, Wegovy, Mounjaro, metformin, or other non-insulin diabetes medicines for insulin.** These are not replacements for insulin in established type 1 diabetes; GLP-1" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q21 | no | semaglutide | **not-a-t1d-use** | "## What to avoid - **Do not substitute Ozempic, Wegovy, Mounjaro, metformin, or other non-insulin diabetes medicines for insulin.** These are not replacements for insulin in established type 1 diabetes; GLP-1" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q11 | no | semaglutide | **not-a-t1d-use** | "tors are not replacements for insulin in type 1 diabetes.** Some may be used only for specific specialist-managed indications; SGLT2 drugs can increase the risk of euglycaemic diabetic ketoacidosis. - **Pr" | Named to rule it out as a T1D treatment or insulin substitute. The other use is "specific specialist-managed indications", read as separate indications (as 651f3039, "selected additional conditions"). |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q16 | no | tirzepatide | **not-a-t1d-use** | "Their Saudi availability does not make them approved primary treatment for T1D. - **SGLT2 inhibitors such as dapagliflozin or empagliflozin:** generally unsui" | Named to rule it out as a T1D treatment or insulin substitute. Listed under what not to buy; the approval sentence reinforces the rule-out and offers no T1D use. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q16 | no | semaglutide | **not-a-t1d-use** | "Their Saudi availability does not make them approved primary treatment for T1D. - **SGLT2 inhibitors such as dapagliflozin or empagliflozin:** generally unsui" | Named to rule it out as a T1D treatment or insulin substitute. Listed under what not to buy; the approval sentence reinforces the rule-out and offers no T1D use. |
| `SA-C20` | 2026-10-11 | 5 | ChatGPT | sa-q03 | no | semaglutide | **indication-absent** | "Agonists:** A retrospective cohort study from Saudi Arabia compared GLP-1 receptor agonists (e.g., semaglutide) with SGLT2 inhibitors in T1D patients over 12 months. The study found that GLP-1 receptor agonists led to significant" | Offered as an adjunctive therapy that "has shown promise", with efficacy findings in T1D; no status statement. |
| `SA-C20` | 2026-10-11 | 5 | Claude | sa-q15 | no | semaglutide | **not-a-t1d-use** | "**Recent Developments:** Novo Nordisk and Lifera signed an MoU in April 2025 to enable local production of semaglutide (GLP-1 treatments) in Saudi Arabia. As a Saudi consumer, you would primarily wo" | Named for local production (market news), not as a T1D use. |
| `SA-C20` | 2026-10-11 | 5 | Claude | sa-q30 | no | tirzepatide | **indication-absent** | "For patients taking GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), the five-year risk of major cardiovascular events such as heart attacks and th" | Outcome figures (MACE -15%, end-stage kidney disease -19%) given in a type 1 results answer without population or status. |
| `SA-C20` | 2026-10-11 | 5 | Claude | sa-q30 | no | semaglutide | **indication-absent** | "For patients taking GLP-1 receptor agonist drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), the five-year risk of major cardiovascular events such as heart attacks and th" | Outcome figures (MACE -15%, end-stage kidney disease -19%) given in a type 1 results answer without population or status; the local-production sentence is a second, market naming. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q20 | no | semaglutide | **not-a-t1d-use** | "but they **do not replace insulin in type 1 diabetes**.[6] Their use in T1D is specialist-directed and may be unsuitable. - **Metformin:** nausea, diarrhea, abdominal discomfort, reduced appetite, and" | Rules it out as an insulin substitute but names specialist-directed use in T1D with no status statement. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q02 | yes | tirzepatide | **not-a-t1d-use** | "**Generally not appropriate as a replacement:** Ozempic, Mounjaro, metformin, SGLT2 inhibitors, and other non-insulin diabet" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q36 | no | tirzepatide | **not-a-t1d-use** | "ic/Wegovy, Mounjaro, SGLT2 inhibitors, or herbal products** do not replace insulin in type 1 diabetes. - Do not purchase insulin online or from an unlicensed seller. - Do not switch" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q36 | no | semaglutide | **not-a-t1d-use** | "ic/Wegovy, Mounjaro, SGLT2 inhibitors, or herbal products** do not replace insulin in type 1 diabetes. - Do not purchase insulin online or from an unlicensed seller. - Do not switch" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q08 | no | tirzepatide | **not-a-t1d-use** | "GLP-1 drugs such as semaglutide and tirzepatide should not be treated as substitutes for insulin in type 1 diabetes; the Saudi market reports about these drugs mainly concern t" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q08 | no | semaglutide | **not-a-t1d-use** | "GLP-1 drugs such as semaglutide and tirzepatide should not be treated as substitutes for insulin in type 1 diabetes; the Saudi market reports about these drugs mainly concern t" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q30 | no | tirzepatide | **not-a-t1d-use** | "- Popular GLP-1 medicines such as Ozempic or Mounjaro are **not replacements for insulin in type 1 diabetes** and should not be self-started for this purpose. ## Practical expectation With" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q04 | no | semaglutide | **not-a-t1d-use** | "- Do not replace insulin with Ozempic/semaglutide, metformin, supplements, or “natural” products. These are not substitutes for i" | Named to rule it out as a T1D treatment or insulin substitute. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q10 | no | tirzepatide | **indication-absent** | "These may have limited specialist uses in selected circumstances, but they cannot replace insulin; stopping insulin can rapidly cause diabetic ketoacidosis. Although metformin i" | Rules it out as an insulin substitute but names specialist use "in selected circumstances" in T1D with no status statement (as G5 of 10 Oct, "selected adjunctive circumstances"; "selected additional conditions" is a separate indication and is not-a-t1d-use). |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q38 | no | tirzepatide | **not-a-t1d-use** | "They are not standard replacement therapy for T1D and can be dangerous if they lead to reduced insulin without specialist supervi" | Named to rule it out as a T1D treatment or insulin substitute. "Primarily for type 2 diabetes or obesity" accompanies the rule-out; no T1D use is offered. |
| `SA-C20` | 2026-10-11 | 5 | Perplexity | sa-q38 | no | semaglutide | **not-a-t1d-use** | "They are not standard replacement therapy for T1D and can be dangerous if they lead to reduced insulin without specialist supervi" | Named to rule it out as a T1D treatment or insulin substitute. "Primarily for type 2 diabetes or obesity" accompanies the rule-out; no T1D use is offered. |

## 6. Non-programme context (descriptive, never coded; T8)

Answers naming a type 1 diabetes agent that is absent from the EASD 2026 programme, per agent: zimislecel 14, baricitinib 4, verapamil 1.

| Agent | Cycle | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|
| zimislecel | `SA-C01` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C03` | 0 | 2 | 0 | 0 |
| zimislecel | `SA-C05` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C06` | 2 | 0 | 0 | 0 |
| zimislecel | `SA-C07` | 1 | 0 | 0 | 0 |
| zimislecel | `SA-C08` | 0 | 0 | 0 | 1 |
| zimislecel | `SA-C11` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C14` | 0 | 0 | 0 | 1 |
| zimislecel | `SA-C15` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C18` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C19` | 0 | 1 | 0 | 0 |
| zimislecel | `SA-C20` | 0 | 1 | 0 | 0 |
| baricitinib | `SA-C02` | 0 | 1 | 0 | 0 |
| baricitinib | `SA-C09` | 0 | 1 | 0 | 0 |
| baricitinib | `SA-C11` | 0 | 1 | 0 | 0 |
| baricitinib | `SA-C14` | 0 | 0 | 0 | 1 |
| verapamil | `SA-C03` | 0 | 1 | 0 | 0 |